TEVA
Teva Pharmaceutical Industries Limited NYSE Listed Feb 16, 1982$31.48
-3.32%
vs $32.56
Mkt Cap $36.9B
52w Low $15.38
76.8% of range
52w High $36.34
50d MA $33.63
200d MA $28.76
P/E (TTM)
26.2x
EV/EBITDA
15.5x
P/B
4.6x
Debt/Equity
2.2x
ROE
19.0%
P/FCF
32.2x
RSI (14)
33.30
ATR (14)
$1.16
Beta
0.76
50d MA
$33.63
200d MA
$28.76
Avg Volume
6.3M
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.
124 Dvora Hanevi'a Street · Tel Aviv 6944020 · IL
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 29, 2026 | TNS | 0.50 | 0.53 | +6.0% | 35.38 | +1.8% | -0.9% | -0.3% | +1.1% | +1.4% | +1.3% | — |
| Jan 28, 2026 | TNS | 0.65 | 0.96 | +47.7% | 33.21 | +0.2% | -0.4% | +3.1% | +4.2% | +2.1% | -3.6% | — |
| Nov 5, 2025 | TNS | 0.68 | 0.78 | +14.7% | 24.60 | -2.2% | -0.6% | -2.0% | +1.2% | +3.6% | +2.8% | — |
| Jul 30, 2025 | TNS | 0.63 | 0.66 | +4.8% | 16.83 | +0.5% | -8.2% | -0.5% | +2.0% | +0.1% | +1.9% | — |
| May 7, 2025 | TNS | 0.47 | 0.52 | +10.6% | 17.60 | -0.5% | +2.7% | -6.3% | +6.1% | -2.7% | -3.4% | — |
| Jan 29, 2025 | TNS | 0.69 | 0.71 | +2.9% | 18.54 | +0.1% | -3.8% | -0.6% | -2.1% | -1.7% | +0.9% | — |
| Nov 6, 2024 | TNS | 0.65 | 0.69 | +6.2% | 17.43 | +1.1% | +0.4% | -2.2% | +1.5% | -1.5% | -1.0% | — |
| Jul 31, 2024 | TNS | 0.57 | 0.61 | +7.0% | 17.43 | -1.0% | +0.6% | -3.1% | -1.8% | +1.4% | -0.7% | — |
| May 8, 2024 | TNS | 0.51 | 0.48 | -5.9% | 15.74 | -0.2% | +1.7% | +1.6% | +3.9% | +1.2% | -1.8% | — |
| Jan 31, 2024 | TNS | 0.75 | 1.00 | +33.3% | 12.10 | +0.6% | +3.0% | -1.4% | +0.8% | -1.1% | -0.9% | — |
| Nov 8, 2023 | TNS | 0.60 | 0.60 | +0.0% | 9.15 | -0.2% | -4.2% | -1.0% | +1.6% | +1.0% | +0.6% | — |
| Aug 2, 2023 | TNS | 0.54 | 0.56 | +3.7% | 9.25 | -1.3% | +3.5% | +2.0% | -1.3% | +1.6% | -1.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 30 | Piper Sandler | Maintains | Overweight → Overweight | — | $35.38 | $36.02 | +1.8% | -0.9% | -0.3% | +1.1% | +1.4% | +1.3% |
| Apr 30 | UBS | Maintains | Buy → Buy | — | $35.38 | $36.02 | +1.8% | -0.9% | -0.3% | +1.1% | +1.4% | +1.3% |
| Apr 30 | Truist | Maintains | Buy → Buy | — | $35.38 | $36.02 | +1.8% | -0.9% | -0.3% | +1.1% | +1.4% | +1.3% |
| Apr 30 | JP Morgan | Maintains | Overweight → Overweight | — | $35.38 | $36.02 | +1.8% | -0.9% | -0.3% | +1.1% | +1.4% | +1.3% |
| Apr 9 | BofA Securities | Maintains | Buy → Buy | — | $30.52 | $30.45 | -0.2% | +1.4% | -0.5% | +1.1% | +2.0% | -0.5% |
| Mar 4 | Piper Sandler | Maintains | Overweight → Overweight | — | $32.28 | $33.18 | +2.8% | +2.0% | -3.5% | -2.2% | +1.4% | +0.1% |
| Feb 18 | Truist | Maintains | Buy → Buy | — | $34.41 | $34.20 | -0.6% | -0.9% | +0.6% | -0.3% | -0.9% | +0.0% |
| Feb 9 | Goldman Sachs | Maintains | Buy → Buy | — | $34.69 | $34.57 | -0.3% | -0.6% | -0.3% | -0.2% | -1.1% | +0.2% |
| Jan 30 | Barclays | Maintains | Overweight → Overweight | — | $33.07 | $32.49 | -1.8% | +3.1% | +4.2% | +2.1% | -3.6% | -0.5% |
| Jan 29 | Truist | Maintains | Buy → Buy | — | $33.21 | $33.26 | +0.2% | -0.4% | +3.1% | +4.2% | +2.1% | -3.6% |
| Jan 29 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $33.21 | $33.26 | +0.2% | -0.4% | +3.1% | +4.2% | +2.1% | -3.6% |
| Jan 6 | Jefferies | Maintains | Buy → Buy | — | $31.00 | $31.63 | +2.0% | +3.6% | +0.9% | +0.3% | -1.5% | +2.4% |
| Dec 22 | Piper Sandler | Maintains | Overweight → Overweight | — | $30.35 | $30.72 | +1.2% | +2.8% | +1.1% | +0.6% | +0.5% | -1.0% |
| Dec 19 | Goldman Sachs | Maintains | Buy → Buy | — | $30.32 | $30.10 | -0.7% | +0.1% | +2.8% | +1.1% | +0.6% | +0.5% |
| Dec 16 | JP Morgan | Maintains | Overweight → Overweight | — | $30.13 | $30.13 | +0.0% | -0.1% | -0.1% | +0.9% | +0.1% | +2.8% |
| Dec 9 | BofA Securities | Maintains | Buy → Buy | — | $28.33 | $29.07 | +2.6% | +0.8% | +4.3% | +1.3% | -1.3% | +1.1% |
| Dec 8 | Goldman Sachs | Maintains | Buy → Buy | — | $28.46 | $28.74 | +1.0% | -0.5% | +0.8% | +4.3% | +1.3% | -1.3% |
| Nov 6 | JP Morgan | Maintains | Overweight → Overweight | — | $24.60 | $24.05 | -2.2% | -0.6% | -2.0% | +1.2% | +3.6% | +2.8% |
| Oct 3 | JP Morgan | Maintains | Overweight → Overweight | — | $20.05 | $20.17 | +0.6% | -0.2% | -0.2% | +0.6% | +0.7% | -0.8% |
| Sep 24 | UBS | Maintains | Buy → Buy | — | $19.45 | $19.45 | +0.0% | -0.9% | -4.7% | -0.1% | +4.6% | +5.3% |
| Jun 26 | UBS | Maintains | Buy → Buy | — | $17.00 | $17.00 | +0.0% | -2.6% | +1.2% | +0.0% | -0.7% | +2.5% |
| May 12 | JP Morgan | Upgrade | Neutral → Overweight | — | $16.93 | $17.25 | +1.9% | +6.1% | -2.7% | -3.4% | -0.1% | +0.4% |
| May 8 | BofA Securities | Maintains | Buy → Buy | — | $17.60 | $17.52 | -0.5% | +2.7% | -6.3% | +6.1% | -2.7% | -3.4% |
| Mar 6 | BofA Securities | Maintains | Buy → Buy | — | $15.90 | $15.58 | -2.0% | -3.5% | +0.1% | -4.5% | +9.7% | +2.4% |
| Jan 30 | Barclays | Maintains | Overweight → Overweight | — | $18.54 | $18.56 | +0.1% | -3.8% | -0.6% | -2.1% | -1.7% | +0.9% |
| Jan 30 | UBS | Maintains | Buy → Buy | — | $18.54 | $18.56 | +0.1% | -3.8% | -0.6% | -2.1% | -1.7% | +0.9% |
| Jan 23 | UBS | Maintains | Buy → Buy | — | $22.01 | $22.01 | +0.0% | -1.0% | -0.5% | +0.5% | -1.1% | -13.9% |
| Jan 17 | Piper Sandler | Maintains | Overweight → Overweight | — | $21.68 | $21.49 | -0.9% | +1.1% | -0.5% | +0.9% | -1.0% | -0.5% |
| Dec 18 | Barclays | Maintains | Overweight → Overweight | — | $20.88 | $20.45 | -2.1% | +1.5% | +0.5% | +3.7% | +0.5% | +0.9% |
| Oct 23 | Barclays | Maintains | Overweight → Overweight | — | $18.38 | $18.40 | +0.1% | +0.2% | -0.9% | -1.9% | +2.6% | +0.3% |
| Oct 21 | JP Morgan | Maintains | Neutral → Neutral | — | $17.95 | $18.04 | +0.5% | +1.3% | +1.1% | +0.2% | -0.9% | -1.9% |
| Sep 3 | UBS | Maintains | Buy → Buy | — | $18.87 | $18.63 | -1.3% | -1.9% | +2.4% | -2.8% | -1.9% | -1.5% |
| Aug 1 | Barclays | Maintains | Overweight → Overweight | — | $17.43 | $17.25 | -1.0% | +0.6% | -3.1% | -1.8% | +1.4% | -0.7% |
| Jul 10 | UBS | Maintains | Buy → Buy | — | $15.81 | $16.20 | +2.5% | +7.4% | +0.7% | +1.1% | -1.2% | -2.5% |
| Jun 27 | Jefferies | Maintains | Buy → Buy | — | $16.25 | $16.50 | +1.5% | +0.1% | -0.1% | +0.6% | +1.3% | +1.6% |
| Jun 5 | Barclays | Maintains | Overweight → Overweight | — | $16.63 | $16.75 | +0.7% | +1.5% | -1.6% | +1.3% | +0.2% | +2.9% |
| May 30 | BofA Securities | Maintains | Buy → Buy | — | $16.45 | $16.52 | +0.4% | +2.7% | +0.2% | +0.3% | -2.1% | +1.5% |
| May 13 | Piper Sandler | Maintains | Overweight → Overweight | — | $16.25 | $16.30 | +0.3% | +3.9% | +1.2% | -1.8% | -2.9% | -0.1% |
| May 9 | Barclays | Maintains | Overweight → Overweight | — | $15.74 | $15.71 | -0.2% | +1.7% | +1.6% | +3.9% | +1.2% | -1.8% |
| Mar 8 | JP Morgan | Upgrade | Underweight → Neutral | — | $13.71 | $13.69 | -0.1% | -0.7% | -2.0% | +1.0% | +1.2% | -1.1% |
| Feb 12 | Piper Sandler | Upgrade | Neutral → Overweight | — | $12.01 | $12.49 | +4.0% | +7.5% | +0.1% | +1.9% | +0.2% | -1.4% |
| Feb 5 | Barclays | Maintains | Overweight → Overweight | — | $12.28 | $12.27 | -0.1% | +0.8% | -1.1% | -0.9% | -0.4% | -0.7% |
| Feb 5 | Goldman Sachs | Maintains | Neutral → Neutral | — | $12.28 | $12.27 | -0.1% | +0.8% | -1.1% | -0.9% | -0.4% | -0.7% |
| Jan 29 | Barclays | Maintains | Overweight → Overweight | — | $11.91 | $11.86 | -0.4% | -0.7% | -0.8% | +3.2% | +3.0% | -1.4% |
| Jan 23 | Jefferies | Upgrade | Hold → Buy | — | $11.49 | $11.78 | +2.5% | +4.4% | -0.2% | -1.2% | +0.7% | -0.7% |
| Jan 3 | Piper Sandler | Upgrade | Underweight → Neutral | — | $10.67 | $10.86 | +1.8% | +2.6% | -0.6% | +4.1% | +1.2% | -0.6% |
| Nov 27 | UBS | Upgrade | Neutral → Buy | — | $9.55 | $9.82 | +2.8% | +3.5% | -0.8% | -1.1% | +1.3% | -1.1% |
| Sep 20 | UBS | Maintains | Neutral → Neutral | — | $10.29 | $10.38 | +0.9% | +4.0% | -3.4% | +0.1% | -1.0% | -0.3% |
| Sep 8 | BofA Securities | Maintains | Buy → Buy | — | $9.35 | $9.41 | +0.6% | +2.9% | +4.4% | -0.1% | +3.0% | +2.2% |
| Jul 6 | UBS | Upgrade | Sell → Neutral | — | $7.49 | $7.52 | +0.4% | +4.5% | +1.7% | -0.8% | +2.9% | -0.7% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 11, 2026 | Kalif Eliyahu Sharon | EVP, Chief Financial Officer | Sell | 106,563 | $34.10 | $3.6M | 65,621 | -1.06% | — |
| Jun 5, 2026 | Francis Richard D | President and CEO | Sell | 6,153 | $34.35 | $211K | 1,177,529 | +3.58% | -2.71% |
| Jun 3, 2026 | Shields Matthew | EVP, Global Operations | Sell | 16,195 | $32.87 | $532K | 9,989 | -0.70% | +2.92% |
| May 14, 2026 | Lippman Evan | EVP, Business Development | Sell | 35,912 | $35.58 | $1.3M | 44,191 | +0.12% | +1.58% |
| May 14, 2026 | Lippman Evan | EVP, Business Development | Sell | 5,746 | $35.58 | $204K | 6,095 | +0.12% | +1.58% |
| May 14, 2026 | Kalif Eliyahu Sharon | EVP, Chief Financial Officer | Sell | 153,251 | $35.61 | $5.5M | 172,184 | +0.12% | +1.58% |
| May 6, 2026 | Weiss Amir | Chief Accounting Officer | Sell | 10,679 | $36.00 | $384K | 20,016 | -0.78% | -2.59% |
| May 5, 2026 | Daniell Richard | EVP, Europe Commercial | Sell | 30,000 | $35.40 | $1.1M | 55,755 | -0.78% | -2.59% |
| May 1, 2026 | Sabag Mark | See "Remarks" | Sell | 144,180 | $34.99 | $5.0M | 80,760 | +1.44% | +0.31% |
| Apr 30, 2026 | Fox Christine | EVP, U.S. Commercial | Sell | 21,258 | $35.31 | $751K | 63,647 | +1.44% | +0.31% |
No recent filings available.
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Harel Insurance Investments & Financial Services Ltd. | 45,956,714 | $1.4B | Added | Mar 2026 |
| 2 | Phoenix Financial Ltd. | 42,777,414 | $1.3B | Added | Mar 2026 |
| 3 | Menora Mivtachim Holdings Ltd. | 39,626,383 | $1.2B | Added | Mar 2026 |
| 4 | Clal Insurance Enterprises Holdings Ltd | 38,446,506 | $1.1B | Added | Mar 2026 |
| 5 | Migdal Insurance & Financial Holdings Ltd. | 37,902,212 | $1.1B | Added | Mar 2026 |
| 6 | Fmr Llc | 33,132,795 | $998M | Added | Mar 2026 |
| 7 | Lingotto Investment Management Llp | 27,770,857 | $836M | Reduced | Mar 2026 |
| 8 | Morgan Stanley | 16,889,602 | $527M | Added | Dec 2025 |
| 9 | Altshuler Shaham Ltd | 11,463,621 | $335M | New | Mar 2026 |
| 10 | Capital World Investors | 8,833,566 | $266M | Added | Mar 2026 |
| 11 | Northern Trust Corp | 7,635,688 | $230M | Added | Mar 2026 |
| 12 | Glenview Capital Management | 6,660,220 | $201M | New | Mar 2026 |
| 13 | Jpmorgan Chase & Co | 6,762,744 | $192M | Added | Mar 2026 |
| 14 | Alyeska Investment Group, L.p. | 5,519,030 | $166M | Added | Mar 2026 |
| 15 | Janus Henderson Group Plc | 4,816,657 | $145M | New | Mar 2026 |
| 16 | Schroder Investment Management Group | 4,376,270 | $132M | Reduced | Mar 2026 |
| 17 | Bank Of America Corp /de/ | 3,958,814 | $119M | Reduced | Mar 2026 |
| 18 | Invesco Ltd. | 3,253,233 | $98M | Added | Mar 2026 |
| 19 | Nuveen, Llc | 2,741,023 | $83M | Added | Mar 2026 |
| 20 | Lord, Abbett & Co. Llc | 2,412,336 | $73M | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$36.93B
Enterprise Value
$48.64B
P/E (TTM)
26.23x
Forward P/E
11.93x
PEG Ratio
-0.14x
P/B
4.57x
P/S
2.14x
P/FCF
32.17x
EV/EBITDA
15.49x
Shares Out
1.17B
Financials (TTM)
Revenue
$17.26B
Net Income
$1.41B
EBITDA
$3.14B
Free Cash Flow
$1.15B
Op Cash Flow
$1.65B
EPS Basic
$1.23
EPS Diluted
$1.20
EPS Forward
$2.64
Gross Margin
51.8%
Op Margin
12.5%
Net Margin
8.2%
Balance Sheet
Total Assets
$40.75B
Total Liab.
$32.83B
Total Equity
$7.91B
Cash
$3.56B
LT Debt
$15.27B
Book Value/Sh
$6.89
Debt/Equity
2.20x
Current Ratio
1.04
Quick Ratio
0.80
Returns & Growth
ROE
19.0%
ROA
3.9%
ROIC
7.4%
Rev Growth YoY
+4.3%
EPS Growth YoY
+184.8%
Price Returns
2W
+0.0%
1M
+0.7%
3M
+4.3%
6M
+31.3%
12M
+110.5%
Technicals
52W High
$36.34
52W Low
$15.38
50d MA
$33.63
200d MA
$28.76
RSI (14)
33.30
ATR (14)
$1.16
Beta
0.76
Avg Volume
6.3M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
4
Ex-Div Date
Nov 27, 2017
Analyst Price Targets
Consensus
$39.00
High
$42.00
Low
$35.00
Median
$40.00
Data updated apr 27, 2026 4:30am
· Source: financialmodelingprep.com